Investors with losses over $100K in Capricor Therapeutics urged to act

NEW ORLEANS, Sept. 4, 2026 /CourierPR/ -- Investors with losses exceeding $100,000 in Capricor Therapeutics, Inc. (NasdaqGS: CAPR) securities are advised to take swift action. According to ClaimsFiler, a free shareholder information service, investors have until September 28, 2026, to file for lead plaintiff status in a pending class action lawsuit. The lawsuit alleges that Capricor and certain executives failed to disclose material information during the period from December 17, 2025, to July 26, 2026.

On July 27, 2026, the U.S. Food and Drug Administration (FDA) released briefing documents ahead of its advisory committee meeting on July 29. These documents highlighted issues related to the pre-specified statistical analysis plan (SAP) for Capricor’s lead product candidate, Deramiocel. The FDA criticized the company for making changes to the SAP without proper submission and agreement, deeming the post-study SAP versions as post-hoc and exploratory. The FDA’s findings came as a blow, as they suggested a less favorable benefit-risk profile for Deramiocel.

On the same day, Capricor’s stock price plummeted by 64% to close at $7.00 per share, the lowest it had been in months, due to the news. The sharp decline was attributed to the unusually heavy trading volume that day.

The lawsuit, Nkamga v. Capricor Therapeutics, Inc., et al., No. 3:26-cv-04385, is currently pending in the United States District Court for the Southern District of California. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to contact ClaimsFiler for assistance.

Investors can visit ClaimsFiler’s website at <https://claimsfiler.com/cases/nasdaq-capr-2/> or call (833) 538-3604 to learn more about their legal options. The service, which offers free registration, aims to help retail investors recover their share of billions of dollars from securities class action settlements.